Please login to the form below

Not currently logged in
Email:
Password:

FDA reviewers support Optimer antibiotic

Reviewers from the US Food and Drug Administration have issued a positive memo on Optimer Pharmaceuticals' C. difficile treatment fidaxomicin ahead of an advisory committee meeting

Staff reviewers from the US Food and Drug Administration (FDA) have issued a positive memo on Optimer Pharmaceuticals' orally delivered antibiotic fidaxomicin in anticipation of an advisory committee meeting on the drug that is scheduled to take place on Tuesday.

The FDA reviewers said the company's data support the drug's efficacy in treating Clostridium difficile infections, which are characterised by diarrhoea and inflammation of the colon. C. difficile is a common hospital-acquired infection and can be life-threatening, especially in older patients.

In the documents, which are intended to help guide the advisory panel members, the FDA staff reviewers said fidaxomicin worked as well as ViroPharma's Vancocin (vancomycin) in curing C. difficile infections and was better than vancomycin at preventing recurrences of infection.

The FDA reviewers also noted, however, that serious adverse events, including gastrointestinal bleeding, were seen somewhat more often in the fidaxomicin patients than in the vancomycin patients.

Currently, vancomycin is the only FDA-approved drug for C. difficile, although metronidazole is used off-label. About 30 per cent of patients who initially respond to these treatments have a clinical recurrence once drug treatment ends, according to Optimer.

Fidaxomicin, which is Optimer's lead product candidate, could have global sales of about $203m a year, according to a consensus analyst forecast complied by Thomson Reuters. Fidaxomicin is the first in a new class of antibiotics called macrocycles, which inhibit the bacterial enzyme RNA polymerase.

The FDA is due to take action on the marketing application for the drug, which was awarded a priority review, by May 30.

4th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics